Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral BI 3000202 in moderate to severe systemic lupus erythematosus
CTR20261046Phase 2Active
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 3000202 in systemic lupus erythematosus (SLE), sponsored by Boehringer Ingelheim. Started May 2026; status: active.
02
Drugs
BI 3000202
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261046.